Current studies Contact Details Country overview Filter Options Quick Search Filter Options Conditions Activated PI3K delta Syndrome (APDS)Active Ankylosing SpondylitisActive Psoriatic ArthritisAdvanced solid tumorsAlzheimer’s DiseaseAnkylosing SpondylitisAnterior Uveitis (AU)Atopic dermatitisAxial SpondyloarthrithisAxial SpondyloarthritisAxial Spondyloarthritis (axSpA)CDKL5 Deficiency DisorderChildhood absence epilepsyChronic Allograft InjuryChronic inflammatory demyelinating polyradiculoneuropathy (CIDP)Chronic Plaque PsoriasisCrohn's DiseaseDravet SyndromeDrug-resistant EpilepsyEarly-stage parkinson's diseaseElectroencephalographic neonatal seizuresEpilepsyEpilepsy with partial onset seizures or generalized tonic-clonic seizuresEpilepsy with partial-onset seizuresFibromyalgiaFocal-Onset SeizuresGeneralized Myasthenia GravisGeneralized Myasthenia Gravis TESTGeneralized pustular psoriasis and erythrodermic psoriasisHealthy ParticipantsHealthy Study ParticipantsHealthy VolunteersHidradenitis SuppurativaHighly drug-resistant focal epilepsyImmune Mediated Necrotizing MyopathyJuvenile absence epilepsyLennox Gastaut SyndromeLeucine-Rich Glioma Inactivated 1 Autoimmune EncephalitisMixed guttate/plaque psoriasisModerate and severe active Rheumatoid ArthritisModerate chronic plaque psoriasisModerate to Severe Chronic Plaque PsoriasisModerate to Severe Plaque PsoriasisModerate to severe PsoriasisModerately to severely active Crohn's DiseaseMyasthenia GravisMyasthenia Gravis, GeneralizedMyelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD)Nonradiographic Axial Spondyloarthritisnr-axSpAOsteoporosisParkinson DiseaseParkinson's DiseaseParkinson’s diseaseParoxysmal Nocturnal Hemoglobinuria (PNH)Partial SeizuresPartial seizures with or without secondary generalizationPartial-onset SeizuresPlaque PsoriasisPolyarticular-course Juvenile Idiopathic Arthritis (JIA)Primary Immune ThrombocytopeniaProgressive Supranuclear PalsyPsoriasisPsoriatic Arthritisr-axSpaRestless Legs SyndromeRheumatoid ArthritisSevere Active Ulcerative ColitisSevere chronic plaque psoriasisStereotypical prolonged seizuresSystemic lupus erythematosusSystemic Lupus Erythematosus (SLE)ThrombocytopeniaThymidine Kinase 2 (TK2) DeficiencyThymidine Kinase 2 Deficiency Studies That Include Woman Man All Studies Incorporating These Age Groups 0-17 18-65 66+ All ages Product Name Bepranemab Bimekizumab Bimzelx® Brivaracetam Briviact® Certolizumab pegol Cimzia® Dapirolizumab pegol EVENITY Fintepla Ginisortamab Keppra® Lacosamide Levetiracetam Neupro® RA101495 Romosozumab Rotigotine Rozanolixizumab RYSTIGGO Staccato Alprazolam UCB0022 UCB0107 UCB0599 UCB1381 UCB6114 UCB7665 UCB7853 UCB7858 UCB9741 Vimpat® Zampilimab ZILBRYSQ® Zilucoplan Status Recruiting Not yet recruiting Enrolling by invitation Active, not recruiting Study Title Minimum Age Maximum age Studies That Include Status A Phase 2 Open-Label Study of Continuation Treatment with Combination Pyrimidine Nucleosides in Patients with Thymidine Kinase 2 Deficiency (TK2) - - All Active, not recruiting A Phase 2 Open-Label Study of Continuation Treatment with Combination Pyrimidine Nucleosides in Patients with Thymidine Kinase 2 Deficiency (TK2) Thymidine Kinase 2 Deficiency Learn More An Open-Label, Single Center, Randomized, 2-Way Crossover, Single-Dose, Bioequivalence Study of Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-Injector in Healthy Adult Participants 18 Years 55 Years All Active, not recruiting An Open-Label, Single Center, Randomized, 2-Way Crossover, Single-Dose, Bioequivalence Study of Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-Injector in Healthy Adult Participants Healthy Volunteers Learn More A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis 18 Years - All Active, not recruiting A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis Chronic Plaque Psoriasis Learn More An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy for Seizures in Patients with Rare Seizure Disorders Such as Epileptic Encephalopathies Including Dravet Syndrome and Lennox-Gastaut Syndrome 2 Years - All Active, not recruiting An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy for Seizures in Patients with Rare Seizure Disorders Such as Epileptic Encephalopathies Including Dravet Syndrome and Lennox-Gastaut Syndrome Dravet Syndrome Learn More A Phase 3b, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Participants With Generalized Myasthenia Gravis Switching From Intravenous Complement Component 5 Inhibitors to Subcutaneous Zilucoplan 18 Years 85 Years All Active, not recruiting A Phase 3b, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Participants With Generalized Myasthenia Gravis Switching From Intravenous Complement Component 5 Inhibitors to Subcutaneous Zilucoplan Generalized Myasthenia Gravis Learn More A Dose-Blinded Extension Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of UCB0599 in Study Participants With Parkinson's Disease 40 Years 78 Years All Active, not recruiting A Dose-Blinded Extension Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of UCB0599 in Study Participants With Parkinson's Disease Parkinson’s disease Learn More A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis 18 Years - All Active, not recruiting A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis Psoriatic Arthritis, Moderate to Severe Chronic Plaque Psoriasis, Chronic Plaque Psoriasis Learn More A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa 18 Years - All Active, not recruiting A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa Hidradenitis Suppurativa Learn More A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis 18 Years - All Active, not recruiting A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis Generalized Myasthenia Gravis Learn More A Multicenter, Open-Label, Randomized Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis 12 Years 17 Years All Active, not recruiting A Multicenter, Open-Label, Randomized Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis Moderate to Severe Plaque Psoriasis Learn More A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer’s Disease (AD), Followed by an Open-Label Extension Period 50 Years 80 Years All Active, not recruiting A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer’s Disease (AD), Followed by an Open-Label Extension Period Alzheimer’s Disease Learn More Open-Label, Single-Arm, Multicenter Study to Evaluate Long-Term Safety and Tolerability of Brivaracetam Used as Adjunctive Treatment in Pediatric Study Participants With Epilepsy 1 Months - All Active, not recruiting Open-Label, Single-Arm, Multicenter Study to Evaluate Long-Term Safety and Tolerability of Brivaracetam Used as Adjunctive Treatment in Pediatric Study Participants With Epilepsy Epilepsy Learn More An Open-Label Extension Study to Evaluate the Safety and Tolerability of Long-Term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy 40 Years - All Active, not recruiting An Open-Label Extension Study to Evaluate the Safety and Tolerability of Long-Term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy Progressive Supranuclear Palsy Learn More A Multicenter, Open-Label, Follow-Up Study to Assess the Long-Term Use of Oral Lacosamide in Study Participants Who Completed EP0034 or SP848 and Received Lacosamide Treatment 2 Years 5 Years All Active, not recruiting A Multicenter, Open-Label, Follow-Up Study to Assess the Long-Term Use of Oral Lacosamide in Study Participants Who Completed EP0034 or SP848 and Received Lacosamide Treatment Epilepsy Learn More A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis 18 Years - All Active, not recruiting A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis Psoriatic Arthritis Learn More A Multicenter, Open-Label Extension Study to Asses the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Study Participants With Active Axial Spondyloarthritis, Ankylosing Spondylitis, and Nonradiographic Axial Spondyloarthritis 18 Years - All Active, not recruiting A Multicenter, Open-Label Extension Study to Asses the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Study Participants With Active Axial Spondyloarthritis, Ankylosing Spondylitis, and Nonradiographic Axial Spondyloarthritis Axial Spondyloarthritis Learn More A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy >=1 Month to <4 Years of Age With Partial-Onset Seizures 1 Months 47 Months All Active, not recruiting A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy >=1 Month to <4 Years of Age With Partial-Onset Seizures Epilepsy with partial-onset seizures Learn More
